NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kinea Bio, Inc.

Kinea Bio, Inc.

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://kineabio.com/

Last Round

Grant

Sep 23, 2025

Total Funding Raised

$3.94M

Company Overview

Kinea Bio, Inc. is a biotechnology company that develops next-generation AAV-based gene therapies to treat neuromuscular diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyadeno-associated virusAAVdual-AAV vectorneuromuscular diseasegenetic medicinebiotechmyotropic capsidsnanovesicle deliveryDuchenne muscular dystrophydysferlinopathypreclinical researchdrug delivery platformgene therapy deliveryrare disease therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kinea Bio, Inc. Comps

Public and private peers based on sector, stage, and business model.

Kinea Bio, Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kinea Bio, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 23, 2025
GrantSep 15, 2025
GrantJun 9, 2025
GrantSep 10, 2024
SeedFeb 13, 2024

Key People

Founding team and executive leadership

Nicholas Geisse

Co-Founder, Acting COO

Founding Team

Martin K. Childers

Chief Executive Officer

Executive Team

Michael Cho

CFO & Chief Strategy Officer

Executive Team

Seung Wook Oh

COO

Executive Team

Kinea Bio, Inc. Investors

Notable investors and investment history

Kinea Bio, Inc. investors
InvestorRounds
Parent Project Muscular DystrophySeed
NIH RADxGrant
The Jain FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 22, 2026

    Monthly visitors increased 111% MoM, reaching 2.3K.

  • Jun 9, 2025

    Secured $2M from NIH RADx.

Kinea Bio, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kinea Bio, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kinea Bio, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range5
Year Founded2020
Last FundingSep 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.